← Back to Search

Acupuncture for Breast Cancer

N/A

Waitlist Available

Led By Ting Bao, MD, DABMA, MS

Research Sponsored by Memorial Sloan Kettering Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 2 years

Awards & highlights

Study Summary

This trial is testing whether acupuncture can help reduce nerve damage from chemotherapy and improve quality of life.

Eligible Conditions

Breast Cancer
Peripheral Neuropathy

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 2 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~2 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

CIPN severity as measured by National Cancer Institute-Common Toxicity Criteria version 4.0

Secondary outcome measures

CIPN severity as measured by FACT/GOG-Nts

Side effects data

From 2013 Phase 1 & 2 trial • 104 Patients • NCT01305811

Serious unexpected

Pain on needling

100%

80%

60%

40%

20%

Study treatment Arm

Bi-Weekly Acupuncture

Wait List

Trial Design

1Treatment groups

Experimental Treatment

Group I: AcupunctureExperimental Treatment3 Interventions

As part of routine clinical care, a chemotherapy nurse, research nurse, or physician will assess the patient's symptoms including CIPN based on the NCI-CTC 4.0 criteria to determine the grade of CIPN. Once these patients develop National Cancer Institute-Common Toxicity Criteria (NCI-CTC) grade 2 CIPN, they will be recruited for the intervention phase of the study. Severity of CIPN as defined by NCI-CTC is listed in Appendix A. Patients who consent to the intervention phase of the study will then be treated with weekly acupuncture until the end of chemotherapy. No concomitant anti-neuropathy medication will be permitted. Subjects will receive acupuncture in bilateral ear points: shen men, point zero, two additional auricular acupuncture point where electrodermal signal is detected and bilateral body acupuncture points: LI4, TE5, LI11, ST40, Ba Feng, Ba xie.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

FACT/GOG-Ntx questionnaire

2015

N/A

~30

Neuropathic Pain Scale (NPS) questionnaire

2015

N/A

~30

Acupuncture

2011

Completed Phase 3

~1240

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Memorial Sloan Kettering Cancer CenterLead Sponsor

1,935 Previous Clinical Trials

588,833 Total Patients Enrolled

202 Trials studying Breast Cancer

81,109 Patients Enrolled for Breast Cancer

Ting Bao, MD, DABMA, MSPrincipal InvestigatorMemorial Sloan Kettering Cancer Center

3 Previous Clinical Trials

593 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any openings for participants in this medical trial?

"Clinicaltrials.gov affirms that this particular medical trial is not actively recruiting patients at the moment, as its last update was on March 1st 2022. While 2745 other clinical trials are currently accepting participants, this one is not among them."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Acupuncture to Reduce Chemotherapy-induced Peripheral Neuropathy Severity During Neoadjuvant or Adjuvant Weekly Paclitaxel Chemotherapy in Breast Cancer Patients

2015. "Acupuncture to Reduce Chemotherapy-induced Peripheral Neuropathy Severity During Neoadjuvant or Adjuvant Weekly Paclitaxel Chemotherapy in Breast Cancer Patients". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02364726.